Short on time? Our visual summary highlights key insights from #EASL2025 on the AATD liver care journey, designed to fit into your busy schedule. Download now for the updates you need to know on detection, care pathways, and emerging therapies #MedSky #LiverSky
ow.ly/maZ850XCIrT
Short on time? Catch up on advances in AATD liver care relevant to your clinical practice from #EASL2025 with our NEW visual summary. For key points on detection and care pathways, plus emerging therapies at a glance, download our infographic today #MedSky #LiverSky
ow.ly/oAWW50XgYX5
The good news is this methodology has already been piloted in the South West Deanery so we know it can be done! We were delighted to share the initial findings at #EASL2025 @easlnews.bsky.social
(5/6)
Did you hear the NorUrso clinical trial news we announced recently? This is the furthest a drug has progressed in PSC medicine development with positive results. Find out more: pscsupport.org.uk/clinical-tri...
#PSCSupport #LetsBeatPSC #ClinicalTrials #EASL2025 #NorUrso #PSC
How can multidisciplinary care improve outcomes for AATD-associated liver disease? Alice Turner shares her pulmonology perspective and how lung management basics can enhance treatment in this accredited symposium from #EASL2025 #MedSky #LiverSky
ow.ly/mgjN50Wocfc
If we want to improve scientific poster sessions, we have to get good at measuring them.
So I went to Europe's largest liver science conference and attempted to measure how scientists browse posters.
Findings soon. Watch the walkthrough:
youtu.be/ErTfb2plrrU
#ScienceUX #betterposter #EASL2025
With AATD-associated liver disease, symptom-free doesn’t always mean disease-free. Get the latest updates you need to know on managing and diagnosing AATD-associated liver disease from #EASL2025 and earn #CME credit now with Medthority #MedSky #LiverSky
ow.ly/EXXP50Wn4jL
Earn 1 #CME credit with expert insights on AATD-associated liver disease from #EASL2025. Watch the accredited symposium, led by Rohit Loomba, to get the latest updates on the Pi*ZZ genotype, emerging therapies, and the real patient experience #MedSky #MedEd #LiverSky
ow.ly/9TyM50WcojC
🌍 WONCA Europe EB met online 2 June 2025.
🔸 5 Star Doctor Awards announced
🔸 EJGP goes fully online
🔸 Lisbon & Paris conference prep
🔸 EAHA launch at #EASL2025
🔗 Read more: https://pnc.ee/aAyK8Pp
#WONCAEurope #PrimaryCare #GeneralPractice
🔖 How are #steatotic liver diseases tackled today?
Michael Roden points out innovative aspects of the EASL-EASD-EASO Clinical Practice Guidelines on the management of #MASLD discussed at #EASL2025.
📺 Watch here: tinyurl.com/yspxxpbb
🔗 Guidelines: tinyurl.com/mr3bvb2t
@easlnews.bsky.social
🔬 Dr Cynthia Levy shared encouraging results from Ipsen’s Phase 2 ELMWOOD trial (NCT05627362) of elafibranor in PSC.
Results support further trials to explore ELA’s potential as a PSC treatment.
🔗 pscsupport.org.uk/clinical-tri...
#PSC #LiverDisease #ClinicalTrials #EASL2025 #LetsBeatPSC
Dr. Falk Pharma announced long-awaited Phase 3 trial results for norucholic acid (NCA) in #PSC—the furthest any drug has progressed with positive results - live at #EASL2025, with PSC Support’s Paula Hanford & Martine Walmsley there to hear it first-hand.
buff.ly/zdWAyHe
📢 Live PSC Webinar – Sat 17 May, 3:30pm (BST). Dr Palak Trivedi joins us to discuss the breaking research updates from #EASL2025 – with encouraging news for the PSC community.
🎟️ Register for joining details: us06web.zoom.us/webinar/regi...
#PSCsupport #PSCresearch #LetsBeatPSC #AskTheExpert
Dr. Anu Osinusi from Gilead Sciences discusses a global study presented at #EASL2025 that reports a 98.9% SVR rate with SOF/VEL in 7,027 hepatitis C patients across 4 continents. #IDsky #MEDsky #HEPsky #HCV
Listen here: www.contagionlive.com/view/global-...
ICYMI: Interviews w/ Dr. Anu Osinusi from Gilead on data presented at #EASL2025. #IDsky #MEDsky #Hepatitis
Investigational therapy from its phase 3 MYR301 study: www.contagionlive.com/view/hepatit...
Examining bulevirtide as a standalone therapy & combination: www.contagionlive.com/view/gilead-...
At #EASL2025, ELPA President Marko Korenjak presented 3 EU projects: A-TANGO, LIVER AIM & THRIVE.
At the Layperson Events, science met real stories — patients at the center of innovation, action & hope.
@liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social
Yes! And #SharedDecisionMaking is something we need to educate physicians & #HBV patients on.
👉We have to be very intentional about the process, present options &
ask patients what is important to them.
I am often surprised & realize I can’t assume!
#EASL2025
notputtingonashirt.org/2019/11/21/s...
🔬 Improving the prognostic performance of the #MELD score is a challenge that Nikolaj Torp (Odense University Hospital) took on, comparing the original score with MELD 3.0 in 777 patients with an acute #decompensation of #cirrhosis
#POSTER SAT-196-YI 👏
📅 Presented at #EASLCongress | #EASL2025
Late breakers from
#EASLCongress 👇
#EASL2025 #liversky
🧠 SAT-210 – #EASL2025
New tool alert!
The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!
#LiverHealth #HE #ClinicalResearch
🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin
#POSTER SAT-145-YI by Enrico Pompili (UNIBO) proposes a personalized management approach for patients with cirrhosis and ascites, based on real-world data from long-term albumin therapy. #EASL2025
